← Eichor
Study identifier: NCT05986136 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

Condition: Inflammatory Bowel Diseases  ·  Sponsor: Mostafa Bahaa

PhasePhase 2/Phase 3
Planned participants50
Who can joinAll sexes, 18 Months to 60 Years
Healthy volunteersNo

About this study

The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.

This description comes directly from the study's public registry record.

Talk to the study team

Mostafa Bahaa, PhD  ·  0201025538337  ·  mbahaa@horus.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Faculty of Medicine, Mansoura UniversityAl Mansurah, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05986136